A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Posted by & filed under .

This is a Phase I, multicenter, open-label, dose-escalation study of DMUC4064A a dministered by intravenous (IV) infusion every three weeks (q3w) to cancer patie nts. The study will employ a traditional 3 + 3 dose escalation design to determi ne the maximum tolerated dose (MTD) of DMUC4064A against platinum-resistant ovar… Read more »